Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations
Repotrectinib for cancer that has returned or is not responding to treatment
You have cancer that has returned or is not respondin g to treatment You are positive for certain changes in your genes which we will test you for as needed
Exclusion Criteria:
1. You have gastrointestinal disease, such as Crohn’s disease,